Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL17318233 | 0.89 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL10796158 | 0.89 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL1663542 | 0.89 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL1698310 | 0.89 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL17508492 | 0.87 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL6288403 | 0.87 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL27719996 | 0.87 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1ATR | |
| Trifluoromethanesulfonic Acid SCHEMBL5093696 | 0.84 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL261406 | 0.84 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL2167851 | 0.84 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1FFAR3LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383274-B2 | Nonaqueous electrolyte solution for lithium battery, lithium battery using same, and formyloxy group-containing compound used therein | UBE INDUSTRIES, LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110183199-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN | UBE INDUSTRIES, LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183199-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN | HCN2, KCNN2, KCNB1 | ALDH1A1 2190/4885L3MBTL1 1932/4885FFAR3 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.